Market Snapshot
| Study Period: | 2018 - 2026 |
| Base Year: | 2020 |
| CAGR: | 5 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
Asia-Pacific Bladder Cancer Therapeutics and Diagnostics market is expected to register a CAGR of 5% during the forecast period, owing to increasing burden of bladder cancer and new diagnosis & treatments coming up in the market. According to Globocan, 2018, around 37,293 new cases of bladder cancer were registered in Japan and around 9,943 deaths occurred due to it. This calls for the need of early treatment and diagnosis. Furthermore, new drugs are being developed for the treatment of bladder cancer. In 2020, BeiGene Ltd., recieved an approval from China National Medical Products Administration (NMPA) for anti-PD-1 antibody tislelizumab in the treatment of locally advanced or metastatic urothelial carcinoma (UC). Hence, these factors are expected to drive the growth of the market.
Scope of the report
Bladder cancer is a type of tumor that occurs in the cells of the bladder. It grows rapidly and shows uncontrolled growth in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. The Asia-Pacific Bladder Cancer Therapeutics and Diagnostics market is segmented by Product, by Cancer Type, and Geography.
| By Product | ||||||
| ||||||
|
| By Cancer Type | |
| Transitional Cell Bladder Cancer | |
| Squamous Cell Bladder Cancer | |
| Others |
| Geography | ||||||||
|
Key Market Trends
Bladder Ultrasound is Expected to Show a Steady Growth During the Forecast Period
Bladder Ultrasound is one of the type of diagnostic device which uses sound waves to detect and analyze the cancer present in the bladder. The growing incidence of bladder cancer and new devices are being developed for the diagnosis of cancer are expected to stimulate the growth in this segment. According to the Globocan, 2018, almost 4,249 incidences of bladder cancer were observed in the Korea Republic of with around 1,712 deaths. Ultrasound is the most common method used in diagnosing the early stages of cancer due to its specificity. Hence, it is expected to boost the demand for ultrasound devices in the market during the forecast period.
To understand key trends, Download Sample Report
Competitive Landscape
Some of the key players in the market are AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Novartis, Pfizer, Sanofi, Endo Pharmaceuticals Inc. and Johnson & Johnson. Companies are constantly indulged in developing the products related to diagnosis and treatment of the bladder cancer to grow their presence in the market. In 2018, Merck recieved an approval from Japanese Ministry of Health, Labor and Welfare (MHLW) for it's product Keytruda (MSD) which is used for the treatment of urothelial cancer patients.
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Assumptions
-
1.2 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing Burden of Bladder Cancer
-
4.2.2 Innovation in Drug Development
-
-
4.3 Market Restraints
-
4.3.1 Increased Used of Generic Drugs
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Product
-
5.1.1 By Therapeutics
-
5.1.1.1 Chemotherapy
-
5.1.1.2 Immunotherapy
-
5.1.1.3 Others
-
-
5.1.2 By Diagnostics
-
5.1.2.1 Cystoscopy
-
5.1.2.2 Bladder Ultrasound
-
5.1.2.3 Urinalysis
-
5.1.2.4 Others
-
-
-
5.2 By Cancer Type
-
5.2.1 Transitional Cell Bladder Cancer
-
5.2.2 Squamous Cell Bladder Cancer
-
5.2.3 Others
-
-
5.3 Geography
-
5.3.1 Asia-Pacific
-
5.3.1.1 China
-
5.3.1.2 Japan
-
5.3.1.3 India
-
5.3.1.4 Australia
-
5.3.1.5 South Korea
-
5.3.1.6 Rest of Asia-Pacific
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 AstraZeneca Plc
-
6.1.2 Bristol-Myers Squibb Company
-
6.1.3 Eli Lilly & Company
-
6.1.4 Endo Pharmaceuticals Inc.
-
6.1.5 F. Hoffmann-La Roche Ltd
-
6.1.6 GlaxoSmithKline
-
6.1.7 Novartis
-
6.1.8 Pfizer
-
6.1.9 Sanofi
-
6.1.10 Johnson & Johnson
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market market is studied from 2018 - 2026.
What is the growth rate of Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market?
The Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market is growing at a CAGR of 5% over the next 5 years.
Who are the key players in Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market?
F. Hoffmann-La Roche Ltd, Johnson & Johnson, Endo Pharmaceutical Inc., AstraZeneca Plc, Bristol-Myers Squibb Company are the major companies operating in Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market.
